Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/need-for-new-tb-drugs-13991/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/need-for-new-tb-drugs-13991/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/need-for-new-tb-drugs-13991/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/need-for-new-tb-drugs-13991/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0bce8d3533-trace').style.display = (document.getElementById('cakeErr67f0bce8d3533-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f0bce8d3533-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0bce8d3533-code').style.display = (document.getElementById('cakeErr67f0bce8d3533-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0bce8d3533-context').style.display = (document.getElementById('cakeErr67f0bce8d3533-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f0bce8d3533-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f0bce8d3533-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 13868,
		&#039;title&#039; =&gt; &#039;Need for new TB drugs&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;-&lt;/em&gt;The Hindu
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 25 March, 2012, http://www.thehindu.com/health/policy-and-issues/article3220027.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;need-for-new-tb-drugs-13991&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 13991,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 13868,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Need for new TB drugs&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Tuberculosis,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu


&amp;nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;-&lt;/em&gt;The Hindu&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 13868,
	&#039;title&#039; =&gt; &#039;Need for new TB drugs&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;-&lt;/em&gt;The Hindu
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 25 March, 2012, http://www.thehindu.com/health/policy-and-issues/article3220027.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;need-for-new-tb-drugs-13991&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 13991,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 13868
$metaTitle = &#039;LATEST NEWS UPDATES | Need for new TB drugs&#039;
$metaKeywords = &#039;Tuberculosis,Health&#039;
$metaDesc = &#039;
-The Hindu


&amp;nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;-&lt;/em&gt;The Hindu&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/need-for-new-tb-drugs-13991.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Need for new TB drugs | Im4change.org</title>
    <meta name="description" content="
-The Hindu


&nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Need for new TB drugs</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify"><em>-</em>The Hindu</div><div style="text-align: justify">&nbsp;</div><div style="text-align: justify"><em>Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>LACK OF INNOVATION</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)</em></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0bce8d3533-trace').style.display = (document.getElementById('cakeErr67f0bce8d3533-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f0bce8d3533-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0bce8d3533-code').style.display = (document.getElementById('cakeErr67f0bce8d3533-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0bce8d3533-context').style.display = (document.getElementById('cakeErr67f0bce8d3533-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f0bce8d3533-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f0bce8d3533-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 13868,
		&#039;title&#039; =&gt; &#039;Need for new TB drugs&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;-&lt;/em&gt;The Hindu
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 25 March, 2012, http://www.thehindu.com/health/policy-and-issues/article3220027.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;need-for-new-tb-drugs-13991&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 13991,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 13868,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Need for new TB drugs&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Tuberculosis,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu


&amp;nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;-&lt;/em&gt;The Hindu&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 13868,
	&#039;title&#039; =&gt; &#039;Need for new TB drugs&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;-&lt;/em&gt;The Hindu
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 25 March, 2012, http://www.thehindu.com/health/policy-and-issues/article3220027.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;need-for-new-tb-drugs-13991&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 13991,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 13868
$metaTitle = &#039;LATEST NEWS UPDATES | Need for new TB drugs&#039;
$metaKeywords = &#039;Tuberculosis,Health&#039;
$metaDesc = &#039;
-The Hindu


&amp;nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;-&lt;/em&gt;The Hindu&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/need-for-new-tb-drugs-13991.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Need for new TB drugs | Im4change.org</title>
    <meta name="description" content="
-The Hindu


&nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Need for new TB drugs</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify"><em>-</em>The Hindu</div><div style="text-align: justify">&nbsp;</div><div style="text-align: justify"><em>Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>LACK OF INNOVATION</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)</em></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0bce8d3533-trace').style.display = (document.getElementById('cakeErr67f0bce8d3533-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f0bce8d3533-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0bce8d3533-code').style.display = (document.getElementById('cakeErr67f0bce8d3533-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f0bce8d3533-context').style.display = (document.getElementById('cakeErr67f0bce8d3533-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f0bce8d3533-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f0bce8d3533-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 13868,
		&#039;title&#039; =&gt; &#039;Need for new TB drugs&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;-&lt;/em&gt;The Hindu
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 25 March, 2012, http://www.thehindu.com/health/policy-and-issues/article3220027.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;need-for-new-tb-drugs-13991&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 13991,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 13868,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Need for new TB drugs&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Tuberculosis,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu


&amp;nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;-&lt;/em&gt;The Hindu&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 13868,
	&#039;title&#039; =&gt; &#039;Need for new TB drugs&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;-&lt;/em&gt;The Hindu
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 25 March, 2012, http://www.thehindu.com/health/policy-and-issues/article3220027.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;need-for-new-tb-drugs-13991&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 13991,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 13868
$metaTitle = &#039;LATEST NEWS UPDATES | Need for new TB drugs&#039;
$metaKeywords = &#039;Tuberculosis,Health&#039;
$metaDesc = &#039;
-The Hindu


&amp;nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;-&lt;/em&gt;The Hindu&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;LACK OF INNOVATION&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)&lt;/em&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/need-for-new-tb-drugs-13991.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Need for new TB drugs | Im4change.org</title>
    <meta name="description" content="
-The Hindu


&nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Need for new TB drugs</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify"><em>-</em>The Hindu</div><div style="text-align: justify">&nbsp;</div><div style="text-align: justify"><em>Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>LACK OF INNOVATION</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)</em></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 13868,
		'title' => 'Need for new TB drugs',
		'subheading' => '',
		'description' => '<div style="text-align: justify">
<em>-</em>The Hindu
</div>
<div style="text-align: justify">
&nbsp;
</div>
<div style="text-align: justify">
<em>Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day</em>
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
<em>LACK OF INNOVATION</em>
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
<em>(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)</em>
</div>',
		'credit_writer' => 'The Hindu, 25 March, 2012, http://www.thehindu.com/health/policy-and-issues/article3220027.ece',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'need-for-new-tb-drugs-13991',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 13991,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 13868,
	'metaTitle' => 'LATEST NEWS UPDATES | Need for new TB drugs',
	'metaKeywords' => 'Tuberculosis,Health',
	'metaDesc' => '
-The Hindu


&nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),...',
	'disp' => '<div style="text-align: justify"><em>-</em>The Hindu</div><div style="text-align: justify">&nbsp;</div><div style="text-align: justify"><em>Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>LACK OF INNOVATION</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)</em></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 13868,
	'title' => 'Need for new TB drugs',
	'subheading' => '',
	'description' => '<div style="text-align: justify">
<em>-</em>The Hindu
</div>
<div style="text-align: justify">
&nbsp;
</div>
<div style="text-align: justify">
<em>Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day</em>
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
<em>LACK OF INNOVATION</em>
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
<em>(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)</em>
</div>',
	'credit_writer' => 'The Hindu, 25 March, 2012, http://www.thehindu.com/health/policy-and-issues/article3220027.ece',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'need-for-new-tb-drugs-13991',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 13991,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 13868
$metaTitle = 'LATEST NEWS UPDATES | Need for new TB drugs'
$metaKeywords = 'Tuberculosis,Health'
$metaDesc = '
-The Hindu


&nbsp;


Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day





Tuberculosis (TB),...'
$disp = '<div style="text-align: justify"><em>-</em>The Hindu</div><div style="text-align: justify">&nbsp;</div><div style="text-align: justify"><em>Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy.</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>LACK OF INNOVATION</em></div><div style="text-align: justify"><br /></div><div style="text-align: justify">There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases.</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>(Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)</em></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Need for new TB drugs

-The Hindu   Public sector participation in discovering, developing and making a drug available at affordable prices may be the only way to find new cures for diseases like TB, says Pof Samir Brahmachari on the occasion of World Tuberculosis Day Tuberculosis (TB), a raging problem in Europe and Americas till early 20 century, now predominantly affects the developing world where it continues to be a major health problem and is making in roads even into the developed world. Globally, a TB associated death happens every 20 seconds. India has 20 per cent of the global burden of TB. TB is one of the leading causes of mortality in India, with nearly 1000 deaths a day. The firstline treatment for TB comprises of Rimpampicin, Isoniazid, Pyrazinamide and Ethamabutol adminsitered in combination for 6- 9 months, delivered under the DOTS programme. The duration of the treatment and the side effects of the drugs are major reasons for non-compliance which in return catalyses the emergence of Multi Drug Resistant (MDR) and Extremely Drug Resitant (XDR) strains of TB. In such drug resistant cases we have to rely on a regimen of drugs which are not only less effective but are also significantly more toxic and to top it all have to be administered for extended period up to 18 months. The recent reports of extreme varieties of XDR TB from Mumbai raise an alarm bell. Co-morbity situations like TB with HIV or TB in diabetic patients, both of which are prevalent in India, make treatment even more complex. Thus there is an urgent need to introduce not only new TB drugs but also new regiments that are effective and can also reduce the duration of therapy. LACK OF INNOVATION There is a serious lack of innovation of new drugs in TB as no new drugs have been introduced in the last 50 years. This is because of the lack of a sizable market attractive for the large pharmaceutical companies to invest. The global TB drug market is estimated to be only US$ 300-400 million while the cost of discovery and development of a drug is estimated to be manifolds of this figure. In the absence of market incentives, we need to have novel models of innovation to drive research on TB. Public sector research institutions and hospitals have a leading role to play. Public funds are required to be committed to drive research. The Global Alliance for TB (GATB) has been successful in building a pipe line of novel drugs and combinations for TB treatment. The Open Source Drug Discovery (OSDD) initiative of the Council of Scientific and Innovative Research (CSIR), with its first target disease as TB is a working example, which connects a large number of institutions in public and private sector, to promote innovation in TB drug discovery. OSDD in collaboration with GATB is initiating clinical trials of new drugs and combinations for the treatment of MDRTB patients in India. This model of increased public sector participation in discovering, developing and making the drug available to the patient at affordable prices perhaps is the only way to find new cures for neglected diseases. (Prof Brahmachari is Director General, CSIR, with inputs from Tanjore S Balganesh and Zakir Thoma, CSIR OSDD)